Mouse Genome Informatics
cx
    B2mtm1Unc/B2mtm1Unc
Tg(HLA-A/H2-D/B2M)1Dvs/0

NOD.Cg-B2mtm1Unc Tg(HLA-A/H2-D/B2M)1Dvs
Key:
phenotype observed in females WTSI Wellcome Trust Sanger Institute
phenotype observed in males EuPh Europhenome
N normal phenotype
       
immune system
• CD8+ T cells develop, but at significantly reduced numbers (~10%) compared to NOD controls
• HLA-A2.1-restricted T cells from mice as young as 5 weeks of age respond to IGRP (islet-specific glucose-6-phophatase catalytic subunit-related protein) peptides
• islet-infiltrating T cells show different patterns of recognition to various IGRP peptides; peptide 228-236 is immunodominant HLA-A2.1-binding epitope of IGRP in 12-13 week old nondiabetic female mice
• T cells from islets show HLA-A2-restricted cytotoxicity against human HLA-A2.1-positive human pancreatic islets, as well as mouse islets
• 55% of females develop type I diabetes by 30 weeks of age, with significantly accelerated onset compared with non transgenic littermates

hematopoietic system
• CD8+ T cells develop, but at significantly reduced numbers (~10%) compared to NOD controls
• islet-infiltrating T cells show different patterns of recognition to various IGRP peptides; peptide 228-236 is immunodominant HLA-A2.1-binding epitope of IGRP in 12-13 week old nondiabetic female mice
• T cells from islets show HLA-A2-restricted cytotoxicity against human HLA-A2.1-positive human pancreatic islets, as well as mouse islets

Mouse Models of Human Disease
OMIM IDRef(s)
Diabetes Mellitus, Insulin-Dependent; IDDM 222100 J:121685